SBWIC
CELG

Schaper Benz & Wise Investment Counsel’s Celgene Corp CELG Stock Holding History

Schaper Benz & Wise Investment Counsel’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,390
Closed -$203K – 107
2017
Q3 		$203K Buy
+1,390
New +$189K 0.03% 104

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schaper Benz & Wise Investment Counsel's CELG Position: Q4 2017 in Review

Schaper Benz & Wise Investment Counsel sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 1,390 shares — an estimated $203K sold.

Schaper Benz & Wise Investment Counsel first reported a position in CELG in Q3 2017 and held it in 1 quarter. The position peaked at $203K in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Schaper Benz & Wise Investment Counsel reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Schaper Benz & Wise Investment Counsel sold 1,390 Celgene Corp shares in Q4 2017, an estimated $203K.
  • Schaper Benz & Wise Investment Counsel first reported a position in Celgene Corp in Q3 2017 and held it in 1 quarter.
  • Schaper Benz & Wise Investment Counsel's Celgene Corp position peaked at $203K in Q3 2017.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Schaper Benz & Wise Investment Counsel's 13F filing for Q4 2017, filed 26 Jan 2018.